MarketCap
Lineage Cell Therapeutics LCTX
$ 1.02
4.08%
Facebook
X
Telegram
Lineage Cell Therapeutics ROE Ratio | LCTX
Annual ROE Ratio Lineage Cell Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -142.61 | -23.74 | -33.88 | -8.66 | -31.44 | -21.71 | -10.53 | -49.86 | -12.16 | 25.72 | -61.47 | -58.05 | -103.83 | -88.19 | -39.84 | -29.3 | -46.57 | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 25.72 | -142.61 | -43.3 |
Quarterly ROE Ratio Lineage Cell Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -204.58 | -212.25 | -208.0 | -81.49 | -27.75 | -22.51 | -33.18 | -35.83 | -33.55 | -24.34 | -32.16 | -29.8 | -30.78 | -24.45 | -55.88 | -54.6 | -50.18 | -43.1 | -9.55 | -11.08 | -13.98 | -21.46 | -27.54 | -34.09 | -53.9 | -10.37 | -55.13 | 30.59 | 52.68 | -49.84 | -45.33 | -107.63 | -110.31 | -12.28 | 27.75 | 45.4 | 73.38 | 28.57 | -19.56 | -96.69 | -153.54 | -176.84 | -153.51 | -125.51 | -115.59 | -100.0 | -203.52 | -241.67 | -266.56 | -296.5 | -226.98 | -217.88 | -223.81 | -223.54 | -178.49 | -139.81 | -97.81 | -57.65 | -13.05 | -14.93 | -11.74 |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 73.38 | -296.5 | -79.73 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Titan Pharmaceuticals
TTNP
|
-192.87 | - | -3.76 % | $ 3.47 M |  USA |
 |
BioVie
BIVI
|
-92.27 | $ 1.33 | 9.92 % | $ 1.96 M | USA |
 |
Longeveron
LGVN
|
-400.07 | $ 1.82 | 6.43 % | $ 32 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-54.92 | - | 3.16 % | $ 1.9 M | USA |
 |
TCR2 Therapeutics
TCRR
|
-107.78 | - | - | $ 58.1 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-46.9 | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Mustang Bio
MBIO
|
-20.16 | $ 0.39 | 0.15 % | $ 1.91 M | USA |
 |
TFF Pharmaceuticals
TFFP
|
-222.05 | - | -60.05 % | $ 125 K | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-175.75 | $ 1.63 | 1.87 % | $ 2.68 M |  Israel |
 |
Mesoblast Limited
MESO
|
-17.1 | $ 14.26 | 1.13 % | $ 17.2 B |  Australia |
 |
Mirum Pharmaceuticals
MIRM
|
-7.42 | $ 93.81 | 0.28 % | $ 4.71 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-597.64 | - | -15.15 % | $ 60.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
-15.82 | - | - | $ 521 M | USA |
 |
Codexis
CDXS
|
-87.03 | $ 1.09 | 6.37 % | $ 95 M | USA |
 |
MannKind Corporation
MNKD
|
-11.49 | $ 3.91 | 4.0 % | $ 1.2 B | USA |
 |
MediciNova
MNOV
|
28.85 | $ 1.44 | -0.69 % | $ 70.7 M | USA |
 |
Axcella Health
AXLA
|
-1949.71 | - | -16.42 % | $ 249 M | USA |
 |
Merck & Co.
MRK
|
34.7 | $ 146.81 | -0.07 % | $ 367 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
4.58 | - | - | $ 2.02 B | USA |
 |
Tyme Technologies
TYME
|
-29.5 | - | 8.07 % | $ 54 M | USA |
 |
Curis
CRIS
|
-138.81 | $ 0.88 | 3.67 % | $ 11.6 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
-46.78 | $ 34.99 | 3.77 % | $ 147 M | USA |
 |
Завод ДИОД
DIOD
|
3.1 | - | - | - |  Russia |
 |
CorMedix
CRMD
|
40.23 | $ 5.31 | 1.43 % | $ 383 K | USA |
 |
Novartis AG
NVS
|
30.0 | $ 162.64 | 0.44 % | $ 315 B |  Schweiz |
 |
CRISPR Therapeutics AG
CRSP
|
-30.26 | $ 50.09 | 3.15 % | $ 4.5 B | Schweiz |
 |
PDS Biotechnology Corporation
PDSB
|
-81.75 | $ 1.22 | 4.27 % | $ 56.6 M | USA |
 |
Pfizer
PFE
|
8.99 | $ 29.39 | -0.22 % | $ 167 B | USA |
 |
Pharming Group N.V.
PHAR
|
22.12 | $ 12.32 | 0.16 % | $ 8.49 B |  Niderland |
 |
Orgenesis
ORGS
|
128.44 | - | -33.86 % | $ 61.2 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
119.0 | $ 53.74 | -3.26 % | $ 6.45 M | USA |
 |
Фармсинтез
LIFE
|
-51.75 | - | - | - | Russia |
 |
Prothena Corporation plc
PRTA
|
-87.03 | $ 7.93 | 0.51 % | $ 427 M | USA |
 |
Codiak BioSciences
CDAK
|
-69.45 | - | -55.98 % | $ 2.15 M | USA |
 |
DBV Technologies S.A.
DBVT
|
-87.07 | $ 10.54 | 7.55 % | $ 1.47 B |  France |
 |
Rocket Pharmaceuticals
RCKT
|
-80.49 | $ 2.38 | -2.05 % | $ 264 M | USA |
 |
Regeneron Pharmaceuticals
REGN
|
14.41 | $ 904.69 | 0.2 % | $ 94.6 B | USA |
 |
Replimune Group
REPL
|
-188.91 | $ 21.67 | 8.24 % | $ 2.01 B | USA |
 |
DiaMedica Therapeutics
DMAC
|
-58.39 | $ 9.47 | 4.76 % | $ 445 M | USA |
 |
Royalty Pharma plc
RPRX
|
7.94 | $ 67.31 | -0.39 % | $ 28.9 B | USA |
 |
Checkpoint Therapeutics
CKPT
|
445.47 | - | - | $ 169 M | USA |
 |
Rhythm Pharmaceuticals
RYTM
|
-0.14 | $ 111.51 | 6.18 % | $ 7.25 B | USA |
 |
Puma Biotechnology
PBYI
|
23.87 | $ 8.28 | -15.25 % | $ 414 M | USA |
 |
SIGA Technologies
SIGA
|
11.71 | $ 3.12 | 4.55 % | $ 223 M | USA |
 |
Sage Therapeutics
SAGE
|
-86.15 | - | - | $ 527 M | USA |
 |
Taro Pharmaceutical Industries Ltd.
TARO
|
1.47 | - | - | $ 1.62 B | Israel |
 |
Sol-Gel Technologies Ltd.
SLGL
|
-26.86 | $ 61.62 | -2.21 % | $ 172 M | Israel |
 |
SELLAS Life Sciences Group
SLS
|
-37.9 | $ 8.41 | 6.73 % | $ 917 M | USA |
 |
Summit Therapeutics
SMMT
|
-163.86 | $ 16.34 | 15.15 % | $ 12.2 B | Britain |